Cell line · CVCL_1124
Papers34
2 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
1 to 20 of 34
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| RAS inhibition limits oncogenic signaling and tumorigenesis in neuroblastoma regardless of RAS mutational status | Sci Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Neuronal differentiation of neuroblastoma cell lines for neurological disease modeling. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Combined inhibition of PLK4 and PPM1D promotes cell death in cancer cells with 17q amplification. | Cancer Cell Int | 2026 | Its Methods give the RRID and name the line | PubMed | |
| YAP1 Enhances Mesenchymal-Type Gene Expression in Human Adrenergic-Type Neuroblastoma Cells. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Extrachromosomal DNA-Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Sustained cancer-relevant alternative RNA splicing events driven by PRMT5 in high-risk neuroblastoma. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Combined inhibition of histone methyltransferases EZH2 and DOT1L is an effective therapy for neuroblastoma. | Cancer Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma. | Int J Cancer | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. | Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| ERBB and P-glycoprotein inhibitors break resistance in relapsed neuroblastoma models through P-glycoprotein. | Mol Oncol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Antibody-Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization. | Mol Cancer Ther | 2021 | Its Methods give the RRID and name the line | PubMed | |
| GAS7 Deficiency Promotes Metastasis in MYCN-Driven Neuroblastoma. | Cancer Res | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Impact of WIN site inhibitor on the WDR5 interactome. | Cell Rep | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Sindbis viral structural protein cytotoxicity on human neuroblastoma cells. | Pediatr Surg Int | 2020 | Its Methods give the RRID and name the line | PubMed | |
| Cell surface vimentin-positive circulating tumor cell-based relapse prediction in a long-term longitudinal study of postremission neuroblastoma patients. | Int J Cancer | 2020 | Its Methods give the RRID and name the line | PubMed | |
| An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. | Cancer Res | 2019 | Cellosaurus cites it | PubMed | |
| Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines. | Sci Data | 2017 | Cellosaurus cites it | PubMed | |
| A Landscape of Pharmacogenomic Interactions in Cancer. | Cell | 2016 | Cellosaurus cites it | PubMed | |
| Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs. | Transl Oncol | 2013 | Cellosaurus cites it | PubMed | |
| Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. | Nat Genet | 2013 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1124/papers